Upstaging of nonurothelial histology in bladder cancer at the time of surgical treatment in the National Cancer Data Base

被引:6
|
作者
Cohen, Andrew J. [1 ]
Packiam, Vignesh [1 ]
Nottingham, Charles [1 ]
Steinberg, Gary [1 ]
Smith, Norm D. [1 ]
Patel, Sanjay [2 ]
机构
[1] Univ Chicago Med, Dept Surg, Urol Sect, Chicago, IL 60637 USA
[2] Univ Oklahoma, Dept Urol, Oklahoma City, OK USA
关键词
Adenocarcinoma; Bladder cancer; Prognosis; Squamous; Small cell; SMALL-CELL CARCINOMA; UROTHELIAL CARCINOMA; NEOADJUVANT CHEMOTHERAPY; PARTIAL CYSTECTOMY; RADICAL CYSTECTOMY; URINARY-BLADDER; RISK-FACTORS; SURVIVAL; ADENOCARCINOMAS; DIFFERENTIATION;
D O I
10.1016/j.urolonc.2016.08.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine patient and pathologic characteristics as well as outcomes for patients with clinically localized, nonurothelial histology bladder cancer. Materials and methods: Using the National Cancer Data Base, we identified patients between 2000 and 2010 diagnosed with bladder cancer as their only malignancy undergoing definitive surgical management. Patients were characterized as urothelial (n = 13,442), squamous (n = 789), small cell (n = 124), adenocarcinoma (n = 789), or other histology (n = 499). Patient and pathologic characteristics were compared across histologic subtypes. We also evaluated for incidence of T and N upstaging. Survival analysis was performed using the Kaplan-Meier method. Multivariate survival analysis was performed to identify predictors of adverse overall survival. Results: Patients with nonurothelial histology were more likely to be African-American, treated at academic medical centers, and of younger age (all P < 0.05). Among those with nonurothelial histology, 55.4% of patients presenting with clinical stage T1 or less had their tumor upstaged during definitive surgical treatment compared to 42.7% of those with urothelial carcinoma. Squamous histology incurred the highest upgrading rate of 61.8%. Five-year survival varied by subtype, with universally decreased survival for those upstaged. Among nonurothelial histology, overall 5-year survival was 32.4% (95% CI: 28.8%-36.2%) vs. 46.0% (95% CI: 42.3%-49.6%) for those upstaged and not upstaged, respectively. Neoadjuvant therapy is used infrequently in this population. Conclusion: We present the largest survival analysis of various rare subtypes of bladder cancer to date. Patients with nonurothelial bladder cancer have significantly higher rate of upstaging at cystectomy and with this a worsened overall survival. Aggressive treatment should be strongly considered for nonurothelial cancers when identified. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:34.e1 / 34.e8
页数:8
相关论文
共 50 条
  • [1] Treatment Patterns and Outcomes of Nonurothelial Cell Carcinoma of the Bladder: Results From the National Cancer Data Base
    Royce, T. J.
    Gray, P. J.
    Lin, C. C.
    Shipley, W. U.
    Jemal, A.
    Efstathiou, J. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E236 - E236
  • [2] Clinical characteristics and outcomes of nonurothelial cell carcinoma of the bladder: Results from the National Cancer Data Base
    Royce, Trevor J.
    Lin, Chun C.
    Gray, Phillip J.
    Shipley, William U.
    Jemal, Ahmedin
    Efstathiou, Jason A.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2018, 36 (02) : 78.e1 - 78.e12
  • [3] Trends in the use of neoadjuvant chemotherapy for bladder cancer with nonurothelial variant histology: An analysis of the National Cancer Database
    Grant, Campbell M.
    Amdur, Richard
    Whalen, Michael J.
    INDIAN JOURNAL OF UROLOGY, 2019, 35 (04) : 291 - 298
  • [4] Nonurothelial cancer of the bladder
    Abol-Enein, Hassan
    Kava, Bruce R.
    Carmack, Adrienne J. K.
    UROLOGY, 2007, 69 : 93 - 104
  • [5] Muscle-invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base
    Smith, Angela B.
    Deal, Allison M.
    Woods, Michael E.
    Wallen, Eric M.
    Pruthi, Raj S.
    Chen, Ronald C.
    Milowsky, Matthew I.
    Nielsen, Matthew E.
    BJU INTERNATIONAL, 2014, 114 (05) : 719 - 726
  • [6] VARIANT HISTOLOGY AS PREDICTOR OF UPSTAGING AT RADICAL CYSTECTOMY FOR UROTHELIAL BLADDER CANCER
    Lonati, Chiara
    Afferi, Luca
    De Cobelli, Ottavio
    Di Trapani, Ettore
    Rink, Michael
    Simeone, Claudio
    Zamboni, Stefania
    Karnes, Robert J.
    Poyet, Cedric
    Simone, Giuseppe
    Hendricksen, Kees
    Einerhand, Sarah H. M.
    Necchi, Andrea
    Montorsi, Francesco
    Briganti, Alberto
    Baumeister, Philipp
    Mattei, Agostino
    Moschini, Marco
    JOURNAL OF UROLOGY, 2021, 206 : E759 - E759
  • [7] Bladder Cancer and the National Cancer Data Base: New Insight or misinformation?
    Choudhury, Ananya
    Hoskin, Peter J.
    CANCER, 2018, 124 (06) : 1105 - 1107
  • [8] The National Cancer Data Base Report on Bladder Carcinoma
    Fleshner, NE
    Herr, HW
    Stewart, AK
    Murphy, GP
    Mettlin, C
    Menck, HR
    CANCER, 1996, 78 (07) : 1505 - 1513
  • [9] Predictors of Pathologic Upstaging in Early Esophageal Cancer Patients: Results from the National Cancer Data Base
    Brown, Craig S.
    Gwilliam, Natalie R.
    Kyrillos, Alexandra
    Lufti, Waseem
    Lapin, Brittany
    Kim, Ki Wan
    Krantz, Seth B.
    Howington, John A.
    Yao, Katherine
    Ujiki, Michael
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2016, 223 (04) : S26 - S26
  • [10] Utilization of surgical treatment for local and locoregional esophageal cancer: Analysis of the National Cancer Data Base
    Taylor, Lauren J.
    Greenberg, Caprice C.
    Lidor, Anne O.
    Leverson, Glen E.
    Maloney, James D.
    Macke, Ryan A.
    CANCER, 2017, 123 (03) : 410 - 419